Biotech | September 12, 2025
iRegene Therapeutics secures series B+ financing
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
